Mode
Text Size
Log in / Sign up
N/A N=120 Randomized Double-blind Prevention

Effect of Remote Ischaemic Preconditioning on Renal Function in Patients Undergoing Living Donor Kidney Transplantation

Kidney Diseases · Kidney Failure, Chronic · Kidney Failure · Renal Insufficiency · Renal Insufficiency, Chronic

Enrolled (actual)
120
Serious AEs
0.0%
Results posted
Sep 2013
Primary outcome: Primary: Plasma Creatine Concentration of the Recipients — 849.5; 878.5; 771.0; 776.5 μmol/l

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
remote ischaemic preconditioning (Device)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Huazhong University of Science and Technology
Primary completion
Nov 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Plasma Creatine Concentration of the Recipients
849.5; 878.5; 771.0; 776.5; 797.5; 725.5
PRIMARY
Urinary Output of the Recipients Postoperatively
175; 300; 100; 1875; 2650; 1850
PRIMARY
Plasma Concentration of NGAL in the Recipients
1478.7; 1269.1; 1377.9; 317.8; 370.1; 256.2
SECONDARY
Acute Rejection of Transplanted Kidney
0; 0; 0
SECONDARY
Delayed Graft Function
1; 2; 2
SECONDARY
Length of Postoperative Hospital Stay
17; 15; 14.5
SECONDARY
Total Costs During the Hospitalization
82499; 83574; 82298
SECONDARY
Urine Concentration of NAG Preoperatively in Recipients
20.79; 15.25; 16.09
SECONDARY
Urine Concentration of NAG Postoperatively in Recipients
16.58; 18.54; 17.06; 3.74; 4.45; 6.46
SECONDARY
Urine Concentration of RBP Preoperatively in the Recipients
2.222; 2.168; 1.964
SECONDARY
Urine Concentration of RBP Postoperatively in the Recipients
2.18; 1.93; 2.05; 2.23; 1.94; 2.27
SECONDARY
Plasma Concentration of SOD in the Recipients
105.04; 96.77; 113.51; 88.86; 94.90; 112.25
SECONDARY
Plasma Concentration of MDA in the Recipients
2.96; 3.34; 3.14; 3.58; 4.15; 3.91

Summary

The purpose of this study was to investigate whether lower limb ischaemic preconditioning can improve renal function in patients undergoing living donor kidney transplantation

Eligibility Criteria

Inclusion Criteria

  • Subject capable of giving written informed consent, with end-stage kidney disease, who is a suitable candidate for primary kidney transplantation
  • Living donors
  • Compatible ABO blood type
  • PRA < 20%

Exclusion Criteria

  • Re-transplant patients
  • Those with peripheral vascular disease affecting the lower limbs
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01289548). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search